Literature DB >> 10386948

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

G W Muller1, R Chen, S Y Huang, L G Corral, L M Wong, R T Patterson, Y Chen, G Kaplan, D I Stirling.   

Abstract

Thalidomide, (1), is a known inhibitor of TNF-alpha release in LPS stimulated human PBMC. Herein we describe the TNF-alpha inhibitory activity of amino substituted analogs of thalidomide (1) and its isoindolin-1-one analog, EM-12 (2). The 4-amino substituted analogs were found to be potent inhibitors of TNF-alpha release in LPS stimulated human PBMC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386948     DOI: 10.1016/s0960-894x(99)00250-4

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  68 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.

Authors:  Masaki Iino
Journal:  Int J Hematol       Date:  2011-12-27       Impact factor: 2.490

3.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 4.  New drugs for the treatment of myelofibrosis.

Authors:  Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

Review 5.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

6.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

Review 7.  Lenalidomide in myeloma.

Authors:  Seema Singhal; Jayesh Mehta
Journal:  Curr Treat Options Oncol       Date:  2007-04

8.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

9.  Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Authors:  Yao Jiang; Jiang Wang; Darlene M Rozewski; Shamalatha Kolli; Chia-Hsien Wu; Ching-Shih Chen; Xiaoxia Yang; Craig C Hofmeister; John C Byrd; Amy J Johnson; Mitch A Phelps
Journal:  J Pharm Biomed Anal       Date:  2013-09-02       Impact factor: 3.935

Review 10.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.